Essential Hypertension
Conditions
Keywords
triple combination, parallel group, dual combination
Brief summary
This study is to determine the change in blood pressure from the administration of Olmesartan/Amlodipine/Hydrochlorothiazide triple combinations compared to dual combinations with Olmesartan/Amlodipine.
Interventions
DRUGolmesartan medoxomil + amlodipine + hydroclororthiazide + placebo
One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
DRUGOlmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo
One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
DRUGolmesartan medoxomil + amlodipine + hydroclororthiazide
One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
DRUGolmesartan medoxomil + amlodipine
One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
Sponsors
Daiichi Sankyo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female subjects aged 18 years or older. * Subjects with mean trough seated blood pressure (SeBP) ≥ 160/100 mmHg, (seated systolic blood pressure(SeSBP) ≥ 160 mmHg and seated diastolic blood pressure (SeDBP) ≥ 100 mmHg) at Screening if not currently on antihypertensive medication (newly diagnosed subjects or subjects who are not taking any antihypertensive medication for at least 3 weeks); Or Subjects with mean trough SeBP ≥ 160/100 mmHg, SeSBP ≥ 160 mmHg and SeDBP ≥ 100 mmHg) after washout of prior antihypertensive medication in subjects who discontinued their previous antihypertensive medication. The difference in mean SeSBP/SeDBP between the visit prior to randomisation and the randomisation visit must be ≤ 20/10 mmHg. Subjects not currently on antihypertensive (HTN) medication may meet this requirement at the screening visit (Visit 1) and the randomization visit (Visit 3). Subjects washing out of HTN medication must meet this requirement at least by Visit 2 (or Visit 2.1, if needed) and Visit 3. All subjects undergoing washout of their prior antihypertensive medication will have the opportunity to re-visit the study sites for additional visits during washout (Visits 2 and 2.1) to assess eligibility for randomisation. * Subjects freely sign the informed consent form (ICF) after the nature of the study and the disclosure of his/her data has been explained. * Female subjects of childbearing potential must be using adequate contraception (female of childbearing potential is defined as one who has not been postmenopausal for at least one year, or has not been surgically sterilised, or has not had a hysterectomy at least three months prior to the start of this study \[Visit 1\]). Adequate contraceptives include hormonal intra-uterine devices, hormonal contraceptives (oral, depot, patch or injectable), and double barrier methods such as condoms or diaphragms with spermicidal gel or foam.
Exclusion criteria
* Female subjects of childbearing potential who are pregnant or lactating. * Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematologic or, neurologic, and psychiatric diseases. The same applies for immunocompromised and/or neutropenic subjects. * Subjects having a history of the following within the last six months: myocardial infarction (MI), unstable angina pectoris, percutaneous coronary intervention, heart failure, hypertensive encephalopathy, cerebrovascular accident (stroke), or transient ischaemic attack. * Subjects with clinically significant abnormal laboratory values at Screening, including subjects with one or more of the following: * Aspartate aminotransferase (AST) \> 3 times upper limit of normal (ULN). * Alanine aminotransferase (ALT) \> 3 times ULN. * Gamma-glutamyl transferase (GGT) \> 3 times ULN. * Potassium above ULN (unless high value is due to haemolytic blood sample). * Subjects with secondary hypertension of any aetiology such as renal disease, phaeochromocytoma, or Cushing's syndrome. * Subjects with contraindication to olmesartan, amlodipine, hydrochlorothiazide, or any of the tablet's excipients. * Newly diagnosed subjects with a mean trough SeSBP \> 200 mmHg or mean trough SeDBP \> 115 mmHg or any subjects with bradycardia (heart rate \< 50 beats/min at rest documented by mean radial pulse rate \[PR\] or electrocardiogram \[ECG\]) at Screening (Visit 1) or immediately before taking Period I study medication (Visit 3). * Subjects already taking four or more antihypertensive medications. * Subjects with a mean trough SeSBP \> 145 mmHg or mean trough SeDBP \> 95 mmHg while taking three antihypertensive medications. * Subjects with a mean trough SeSBP \> 160 mmHg or mean trough SeDBP \> 100 mmHg while taking two antihypertensive medications. * Subjects with a mean trough SeSBP \> 180 mmHg or mean trough SeDBP \> 110 mmHg while taking one antihypertensive medication. * Subjects with electrocardiogram evidence of 2nd or 3rd degree atrio ventricular (AV) block, atrial fibrillation, or other cardiac arrhythmia (requiring treatment). * Subjects with severe heart failure (New York Heart Association stage III-IV), clinically significant aortic or mitral valve stenosis, uncorrected coarctation of the aorta, obstruction of cardiac outflow (obstructive, hypertrophic cardiomyopathy) or symptomatic coronary disease. * Subjects with clinical evidence of renal disease including reno-vascular occlusive disease, nephrectomy and/or renal transplant, bilateral renal artery stenosis, unilateral renal artery stenosis in a solitary kidney, or severe renal impairment as evidenced by CrCl of \< 30 mL/min calculated using the Cockcroft and Gault formula. * Subjects with clinically relevant hepatic impairment. * Subjects with biliary obstruction. * Subjects with uncontrolled Type 1 or Type 2 diabetes defined as HbA1c \> 9.0%. Diabetics must have documentation of HbA1c within 6 months of the Screening Visit, or must have their HbA1c assessed prior to randomisation. Note: subjects with Type 1 or Type 2 diabetes controlled with insulin, diet or oral hypoglycaemic agents on a stable dose for at least 30 days may be included. * Subjects with a history of a wasting disease (e.g. cancer), autoimmune diseases, connective tissue diseases, major allergies or angioneurotic oedema. * Subjects who require or are taking any concomitant medication which may interfere with the objectives of the study. * Subjects on beta blockers or calcium channel blockers (CCBs) for both hypertension and either ischemia, post-MI prophylaxis or tachyarrhythmias. * Subjects with known malabsorption syndromes. * Subjects with psychiatric or emotional problems, which would invalidate the giving of informed consent or limit the ability of the subject to comply with study requirements. * Subjects with a history of alcohol and/or drug abuse. * Subjects who have received any investigational agent within 30 days prior to Screening. * Subjects who are unwilling or unable to provide informed consent or to participate satisfactorily for the entire study. * Subjects with malignancy during the past 2 years excluding squamous cell or basal cell carcinoma of the skin. * Subjects with signs or symptoms which could exacerbate the occurrence of hypotension such as volume and salt depletion. * Subjects with any medical condition, which in the judgment of the Investigator would jeopardise the evaluation of efficacy or safety and/or constitute a significant safety risk to the subject.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Seated Diastolic Blood Pressure (SeDBP). | Baseline to week 10 | Baseline blood pressure was defined as the average values obtained at the randomization visit and at the visit prior to randomization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Reaching Blood Pressure Goal at Week 10 | baseline to week 10 | Blood pressure treatment goal was defined as blood pressure \<140/90 mmHg or \<130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. |
| Change in Seated Diastolic Blood Pressure From Week 18 to Week 22 | Week 18 to week 22 | — |
| Change in Seated Systolic Blood Pressure From Week 18 to Week 22 | Week 18 to week 22 | — |
| Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22 | Week 18 to week 22 | Blood pressure treatment goal was defined as blood pressure \<140/90 mmHg or \<130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. |
| Change in Seated Systolic Blood Pressure (SeDBP). | Baseline to week 10 | — |
| Change in Seated Systolic Blood Pressure From Week 22 to Week 26 | Week 22 to week 26 | — |
| Number of Subjects Reaching Blood Pressure Goal at Week 26 | Week 22 to week 26 | Blood pressure treatment goal was defined as blood pressure \<140/90 mmHg or \<130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. |
| Change in Seated Systolic Blood Pressure (SeDBP) During Open-Label Period VI (Titration Effect From OM/AML/HCTZ 40/5/25 to 40/10/25. | Week 26 to week 54 | — |
| Change in Seated Diastolic Blood Pressure From Week 22 to Week 26 | Week 22 to week 26 | — |
Countries
Belgium, Bulgaria, Czechia, Denmark, Germany, Hungary, Italy, Latvia, Netherlands, Poland, Romania, Russia, Slovakia, Spain, Ukraine
Participant flow
Recruitment details
This study was conduct in Europe from 27 May 2009 to 12 January 2011
Pre-assignment details
Study has randomised, double-blind, placebo-controlled parallel-group portion (Periods I-II) followed by transition phase (Periods III-V) wherein combination titration steps were evaluated in subjects not achieving blood pressure goals. The transition required that all be entered into Period 3 on olm/aml/hctz 20/5/12.5 to ensure a common baseline.
Participants by arm
| Arm | Count |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | 335 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 336 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | 336 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | 336 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | 336 |
| Olmesartan/Amlodipine 20mg/5mg | 337 |
| Olmesartan/Amlodipine 40mg/5mg | 337 |
| Olmesartan/Amlodipine 40mg/10mg | 336 |
| Total | 2,689 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PeriodI-II (Randomized, Double-Blind) | Adverse Event | 11 | 3 | 7 | 13 | 10 | 5 | 9 | 17 | 0 | 0 | 0 | 0 | 0 |
| PeriodI-II (Randomized, Double-Blind) | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PeriodI-II (Randomized, Double-Blind) | Other Reason | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PeriodI-II (Randomized, Double-Blind) | Protocol Violation | 1 | 1 | 1 | 5 | 4 | 2 | 4 | 3 | 0 | 0 | 0 | 0 | 0 |
| PeriodI-II (Randomized, Double-Blind) | Withdrawal by Subject | 4 | 6 | 5 | 8 | 7 | 6 | 5 | 5 | 0 | 0 | 0 | 0 | 0 |
| Period III (Single-Blind) | Adverse Event | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period III (Single-Blind) | Lost to Follow-up | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period III (Single-Blind) | Protocol Violation | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period III (Single-Blind) | Withdrawal by Subject | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period IV (Double-Blind) | Adverse Event | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period IV (Double-Blind) | Protocol Violation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period IV (Double-Blind) | Withdrawal by Subject | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period V (Double -Blind) | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Period V (Double -Blind) | Protocol Violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Period V (Double -Blind) | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Period VI (Open-Label) | Adverse Event | 17 | 0 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period VI (Open-Label) | Lost to Follow-up | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period VI (Open-Label) | Other Reason | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period VI (Open-Label) | Protocol Violation | 6 | 1 | 3 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period VI (Open-Label) | Withdrawal by Subject | 15 | 7 | 5 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | Olmesartan/Amlodipine 20mg/5mg | Olmesartan/Amlodipine 40mg/5mg | Olmesartan/Amlodipine 40mg/10mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 56.0 years STANDARD_DEVIATION 10.81 | 56.8 years STANDARD_DEVIATION 10.36 | 56.5 years STANDARD_DEVIATION 10.92 | 57.0 years STANDARD_DEVIATION 10.72 | 55.9 years STANDARD_DEVIATION 11.08 | 56.1 years STANDARD_DEVIATION 10.22 | 56.4 years STANDARD_DEVIATION 10.4 | 57.0 years STANDARD_DEVIATION 9.7 | 56.5 years STANDARD_DEVIATION 10.53 |
| Race/Ethnicity, Customized Asian | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized Black | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 334 Participants | 336 Participants | 335 Participants | 335 Participants | 336 Participants | 337 Participants | 337 Participants | 335 Participants | 2685 Participants |
| Region of Enrollment Europe | 335 Participants | 336 Participants | 336 Participants | 336 Participants | 336 Participants | 337 Participants | 337 Participants | 336 Participants | 2689 Participants |
| Sex: Female, Male Female | 182 Participants | 171 Participants | 184 Participants | 181 Participants | 178 Participants | 185 Participants | 170 Participants | 192 Participants | 1443 Participants |
| Sex: Female, Male Male | 153 Participants | 165 Participants | 152 Participants | 155 Participants | 158 Participants | 152 Participants | 167 Participants | 144 Participants | 1246 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 12 / 329 | 44 / 334 | 13 / 331 | 39 / 329 | 45 / 332 | 26 / 333 | 38 / 332 | 30 / 325 |
| serious Total, serious adverse events | 55 / 329 | 9 / 334 | 22 / 331 | 3 / 329 | 7 / 332 | 1 / 333 | 5 / 332 | 7 / 325 |
Outcome results
Primary
Change in Seated Diastolic Blood Pressure (SeDBP).
Baseline blood pressure was defined as the average values obtained at the randomization visit and at the visit prior to randomization
Time frame: Baseline to week 10
Population: The full analysis set includes 2679 randomized patients who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period I-II
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | Change in Seated Diastolic Blood Pressure (SeDBP). | -22.5 mm HG | Standard Error 0.48 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | Change in Seated Diastolic Blood Pressure (SeDBP). | -22.5 mm HG | Standard Error 0.48 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | Change in Seated Diastolic Blood Pressure (SeDBP). | -23.0 mm HG | Standard Error 0.48 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | Change in Seated Diastolic Blood Pressure (SeDBP). | -23.9 mm HG | Standard Error 0.47 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | Change in Seated Diastolic Blood Pressure (SeDBP). | -23.8 mm HG | Standard Error 0.48 |
| Olmesartan/Amlodipine 20mg/5mg | Change in Seated Diastolic Blood Pressure (SeDBP). | -20.5 mm HG | Standard Error 0.47 |
| Olmesartan/Amlodipine 40mg/5mg | Change in Seated Diastolic Blood Pressure (SeDBP). | -21.2 mm HG | Standard Error 0.48 |
| Olmesartan/Amlodipine 40mg/10mg | Change in Seated Diastolic Blood Pressure (SeDBP). | -22.1 mm HG | Standard Error 0.48 |
p-value: 0.0071ANCOVA
p-value: 0.0323ANCOVA
p-value: 0.008ANCOVA
p-value: 0.0071ANCOVA
p-value: 0.0107ANCOVA
Secondary
Change in Seated Diastolic Blood Pressure From Week 18 to Week 22
Time frame: Week 18 to week 22
Population: The Full Analysis Set 2=681 randomized participants who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period IV
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | Change in Seated Diastolic Blood Pressure From Week 18 to Week 22 | -3.3 mm Hg | Standard Error 0.47 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | Change in Seated Diastolic Blood Pressure From Week 18 to Week 22 | -4.1 mm Hg | Standard Error 0.37 |
p-value: 0.1135ANCOVA
Secondary
Change in Seated Diastolic Blood Pressure From Week 22 to Week 26
Time frame: Week 22 to week 26
Population: The Full Analysis Set 3=312 randomized participants who received at least one dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period V.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | Change in Seated Diastolic Blood Pressure From Week 22 to Week 26 | -2.7 mm Hg | Standard Error 0.68 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | Change in Seated Diastolic Blood Pressure From Week 22 to Week 26 | -3.8 mm Hg | Standard Error 0.56 |
p-value: 0.1301ANCOVA
p-value: 0.01301ANCOVA
Secondary
Change in Seated Systolic Blood Pressure From Week 18 to Week 22
Time frame: Week 18 to week 22
Population: The Full Analysis Set 2=681 randomized participants who received at least 1 dose of double-blind medication and who provided at least one blood pressure measurement in Period IV
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | Change in Seated Systolic Blood Pressure From Week 18 to Week 22 | -5.7 mm Hg | Standard Error 0.71 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | Change in Seated Systolic Blood Pressure From Week 18 to Week 22 | -6.5 mm Hg | Standard Error 0.56 |
p-value: 0.2765ANCOVA
Secondary
Change in Seated Systolic Blood Pressure From Week 22 to Week 26
Time frame: Week 22 to week 26
Population: The Full Analysis Set 3=312 randomized participants who received at least one dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period V.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | Change in Seated Systolic Blood Pressure From Week 22 to Week 26 | -4.5 mm Hg | Standard Error 1.01 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | Change in Seated Systolic Blood Pressure From Week 22 to Week 26 | -6.7 mm Hg | Standard Error 0.84 |
p-value: 0.0503ANCOVA
Secondary
Change in Seated Systolic Blood Pressure (SeDBP).
Time frame: Baseline to week 10
Population: The full analysis set includes 2679 randomized patients who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period I-II
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | Change in Seated Systolic Blood Pressure (SeDBP). | -33.2 mm Hg | Standard Error 0.72 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | Change in Seated Systolic Blood Pressure (SeDBP). | -33.7 mm Hg | Standard Error 0.72 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | Change in Seated Systolic Blood Pressure (SeDBP). | -35.3 mm Hg | Standard Error 0.71 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | Change in Seated Systolic Blood Pressure (SeDBP). | -35.5 mm Hg | Standard Error 0.71 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | Change in Seated Systolic Blood Pressure (SeDBP). | -36.2 mm Hg | Standard Error 0.72 |
| Olmesartan/Amlodipine 20mg/5mg | Change in Seated Systolic Blood Pressure (SeDBP). | -29.9 mm Hg | Standard Error 0.71 |
| Olmesartan/Amlodipine 40mg/5mg | Change in Seated Systolic Blood Pressure (SeDBP). | -30.4 mm Hg | Standard Error 0.71 |
| Olmesartan/Amlodipine 40mg/10mg | Change in Seated Systolic Blood Pressure (SeDBP). | -32.8 mm Hg | Standard Error 0.71 |
p-value: 0.0006ANCOVA
p-value: 0.0008ANCOVA
p-value: <0.0001ANCOVA
p-value: 0.0034ANCOVA
p-value: 0.0006ANCOVA
Secondary
Change in Seated Systolic Blood Pressure (SeDBP) During Open-Label Period VI (Titration Effect From OM/AML/HCTZ 40/5/25 to 40/10/25.
Time frame: Week 26 to week 54
Population: The number of subjects up titrated who had blood pressure values at both time points.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | Change in Seated Systolic Blood Pressure (SeDBP) During Open-Label Period VI (Titration Effect From OM/AML/HCTZ 40/5/25 to 40/10/25. | -11.9 mm Hg | Standard Deviation 11.01 |
Secondary
Number of Subjects Reaching Blood Pressure Goal at Week 10
Blood pressure treatment goal was defined as blood pressure \<140/90 mmHg or \<130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.
Time frame: baseline to week 10
Population: The full analysis set includes 2679 randomized patients who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period I-II
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | Number of Subjects Reaching Blood Pressure Goal at Week 10 | 177 Participants |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | Number of Subjects Reaching Blood Pressure Goal at Week 10 | 176 Participants |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | Number of Subjects Reaching Blood Pressure Goal at Week 10 | 197 Participants |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | Number of Subjects Reaching Blood Pressure Goal at Week 10 | 190 Participants |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | Number of Subjects Reaching Blood Pressure Goal at Week 10 | 179 Participants |
| Olmesartan/Amlodipine 20mg/5mg | Number of Subjects Reaching Blood Pressure Goal at Week 10 | 144 Participants |
| Olmesartan/Amlodipine 40mg/5mg | Number of Subjects Reaching Blood Pressure Goal at Week 10 | 155 Participants |
| Olmesartan/Amlodipine 40mg/10mg | Number of Subjects Reaching Blood Pressure Goal at Week 10 | 166 Participants |
p-value: 0.0295Cochran-Mantel-Haenszel
p-value: 0.2529Cochran-Mantel-Haenszel
p-value: 0.0037Cochran-Mantel-Haenszel
p-value: 0.2033Cochran-Mantel-Haenszel
p-value: 0.2529Cochran-Mantel-Haenszel
Secondary
Number of Subjects Reaching Blood Pressure Goal at Week 26
Blood pressure treatment goal was defined as blood pressure \<140/90 mmHg or \<130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.
Time frame: Week 22 to week 26
Population: The Full Analysis Set 3=312 randomized participants who received at least one dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period V
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | Number of Subjects Reaching Blood Pressure Goal at Week 26 | 29 Participants |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | Number of Subjects Reaching Blood Pressure Goal at Week 26 | 47 Participants |
Secondary
Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22
Blood pressure treatment goal was defined as blood pressure \<140/90 mmHg or \<130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.
Time frame: Week 18 to week 22
Population: The Full Analysis Set 2=681 randomized participants who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period IV
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22 | 63 Participants |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22 | 137 Participants |
p-value: 0.4964Cochran-Mantel-Haenszel